283
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment

, , , , &
Pages 13-19 | Received 30 Jun 2016, Accepted 06 Oct 2016, Published online: 04 Nov 2016

References

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
  • Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006;11:1388–413.
  • Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010;46:3040–52.
  • Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
  • Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a qua8lity-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
  • Räsänen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynänen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care 2006;22:235–41.
  • Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008;26:1355–63.
  • Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ 2010;11:427–34.
  • Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res 2004;13:1247–53.
  • Wu EQ, Mulani P, Farrell MH, Sleep D. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health 2007;10:408–14.
  • Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health 2009;12:1151–7.
  • Koskinen S, Lundqvist A, Ristiluoma N, eds. Health, functional capacity and welfare in Finland in 2011. Report 68/2012. National institute for health and welfare (THL), Helsinki; 2012. Available from: http://Urn.fi/URN:ISBN:978-952-245-769-1.
  • Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001;33:328–36.
  • Alanne S, Roine RP, Räsänen P, Vainiola T, Sintonen H. Estimating the minimum important change in the 15D scores. Qual Life Res 2015;24:599–606.
  • Fayers PM, Aaronson NK, Bjorkdal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organization for Research and Treatment of Cancer; 2001.
  • Torvinen S, Färkkilä N, Sintonen H, Saarto T, Roine RP, Taari K. Health-related quality of life in prostate cancer. Acta Oncol 2013;52:1094–101.
  • Finnish Cancer Registry. [Internet] [cited 2016 sep 7]. Available from: www.syoparekisteri.fi.
  • Pappa E, Kontodimopoulos N, Papadopoulos AA, Niakas D. Assessing the socio-economic and demographic impact on health-related quality of life: evidence from Greece. Int J Public Health 2009;54:241–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.